
    
      The study was a 6 months randomised placebo controlled trial of adults with GHD and type 2
      diabetes. All receive GH (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and are
      randomised to IGF-I or placebo (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
      Glucose metabolism is evaluated with euglycemic hyperinsulinemic clamp and body composition
      by computed tomography (CT) and bio impedance;.
    
  